Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom
Daire Hanna, Sophie Merrick, Aruni Ghose, Michael Devlin, Dorothy Yang, Edward Phillips, Alicia Okines, Neha Chopra, Elisavet Papadimatraki, Kirsty Ross, Iain R. Macpherson, Zhuang Y. Boh, Caroline O. Michie, Angela Swampillai, Sunnia Gupta, Tim Robinson, Lewis Germain, Chris Twelves, Charlotte Atkinson, Apostolos Konstantis, Pippa Riddle, Nicola Cresti, Jay Naik, Annabel Borley, Amy Guppy, Peter Schmid, Melissa Phillips
Abstract
BACKGROUND: Treatment options for pre-treated patients with metastatic triple-negative breast cancer (mTNBC) remain limited. This is the first study to assess the real-world safety and efficacy of sacituzumab govitecan (SG) in the UK. METHODS: Data was retrospectively collected from 16 tertiary UK cancer centres. Pts had a diagnosis of mTNBC, received at least two prior lines of treatment (with at least one being in the metastatic setting) and received at least one dose of SG. RESULTS: 132 pts were included. Median age was 56 years (28-91). All patients were ECOG performance status (PS) 0-3 (PS0; 39, PS1; 76, PS2; 16, PS3;1). 75% (99/132) of pts had visceral metastases including 18% (24/132) of pts with CNS disease. Median PFS (mPFS) was 5.2 months (95% CI 4.5-6.6) with a median OS (mOS) of 8.7 months (95% CI 6.8-NA). The most common adverse events (AEs) were fatigue (all grade; 82%, G3/4; 14%), neutropenia (all grade; 55%, G3/4; 29%), diarrhoea (all grade; 58%, G3/4, 15%), and nausea (all grade; 38%, G3/4; 3%). SG dose reduction was required in 54% of pts. CONCLUSION: This study supports significant anti-tumour activity in heavily pre-treated pts with mTNBC. Toxicity data aligns with clinical trial experience.